Category Archives: Biotechnology

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Corporate" conference to their offering.

The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference.

This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference.

The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate biotechnology communities.

Benefits of Attending

- Exchange ideas and network with leading biotechnologists and decision makers.

- Bring together top international biotechnology professionals presenting cutting-edge discoveries, research and opportunities for new biotech business practices and partnerships.

- Participants can gain direct access to a core audience of biotechnology professionals and decision makers, and have increased visibility through branding and networking at the conference.

- Obtain a global roundup of Pharmaceutical research capabilities and opportunities.

- The conference will feature a commercial exhibition and poster sessions.

For more information about this conference visit http://www.researchandmarkets.com/research/k2mmsx/global

More:
Global Biotechnology Congress 2017 - Corporate Registration ... - Business Wire (press release)

On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI - Free Report) .

Puma Biotechnology is a development-stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care.

The company posted narrower-than-expected loss in the first quarter of 2017. Reported loss of $1.97 per share was also narrower than year-ago figure of $2.19. With no approved products in its portfolio at the moment, the company does not generate revenues yet. The company reported first-quarter results on May 10, 2017.

So far this year, Pumas shares have outperformed Zacks classified Medical-Biomed/Genetics industry. The companys shares have gained 4.1% while the industry registered an increase of 2.2%.

Puma has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for HER2+ breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market.

We note that several additional studies on neratinib targeting different types of breast cancer patient populations are currently underway. During the quarter, Puma presented encouraging data from several ongoing studies on neratinib at the annual meeting of the American Association for Cancer Research (AACR).

Puma also expects to achieve several milestones in the second quarter of 2017. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

However, dependence on the successful development of a single candidate may hurt the companys growth prospects in case of any adverse development or regulatory setback.

Moreover, lack of partnership deals could hamper progress of the candidate as the company has no sales, marketing or distribution capabilities.

Zacks Rank & Key Picks

Puma currently carries a Zacks Rank #2 (Buy). Other stocks in the health care sector that warrant a look include Aeglea BioTherapeutics (AGLE - Free Report) , VIVUS, Inc. (VVUS - Free Report) and MEI Pharma, Inc. (MEIP - Free Report) . While Aeglea carries a Zacks Rank #2, VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks #1 Rank stocks here.

Aegleas loss per share estimates narrowed from $3.64 to $2.48 for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20.75%.

VIVUSs loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.

MEI Pharmas posted positive earnings surprises in three of the four trailing quarters with an average beat of 66.56%. The companys shares gained 16% so far this year.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Read more here:
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now - Zacks.com

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer.

The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects.

CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models.

Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.

CDRDs Head of Biologics Dr. Ismael Samudio commented, This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics technology and help bring new therapeutic treatments to market.

It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.

About Novelogics Biotechnology, Inc.

Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind we want to create better cancer treatments. http://www.novelogics.com

Novelogics Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

About The Centre for Drug Research and Development (CDRD)

CDRD is Canadas national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. Canadas Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). http://www.cdrd.ca

See the article here:
Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment - Business Wire (press release)

Dr Rose Gidado

Biotechnology is a modern science tool used by most countries to improve agricultural productivity, thereby eliminating hunger and ensuring food security for their populace.

Genetically Modified Organisms (GMOs) is one of the components of biotechnology which is a science tool used to engineer the genes of plants to make them behave in the manner of which they were engineered for.

GMOs have become a topical issue in Nigeria since the country have had problem of providing enough food for the populace. Recently, famine was reported to have reached some parts of the northern Nigeria.

In the quest to ensure food security in the country, some experts have called on the Nigerian government to adopt the new technology of GMOs to increase productivity.

In Nigeria, GMOs have received some criticisms from some groups, arguing the safety of the crops which the genes have been engineered.

Meanwhile, some scientists have said that the GM seeds are like other conventional seeds and does not contain any harmful or toxic contents.

Recently, the Open Forum of Agricultural Biotechnology (OFAB) gathered professionals to brainstorm on how best to convey the message of science to Nigerians.

In Nigeria, farmers who will be the users of this technology if it is adopted in the country are yet to know about the technology, most of them have not heard of the technology.

The Country Coordinator of OFAB, Dr Rose Gidado during the Agricultural Biotechnology and Biosafety Workshop for Professional Bodies Cadre, said the Forum had carried the biotechnology campaign to farmers.

She said the workshop is expected to expand the scope of OFAB and build the capacity of the participants, so that they can understand what the biotechnology is all about.

According to her the objective of the workshop is that we are trying to expand our scope, we are trying to build the capacity of the participants because science is multi faceted, so they need to understand better what we are doing so that they can join in the campaign for GMOs in Nigeria.

Gidado also said that other professional bodies are needed in the campaign, having in mind the huge benefits of this technology to Nigerian populace and the economy.

We need other professional bodies to join us in this campaign because it is all about science. This technology is all about science, it is evidence based, it is important, it can contribute to the socio-economic of Nigeria.

Meanwhile, the Director-General of the National Agricultural Seed Council, Dr Philip Ojo said before the introduction of any Genetically Modified seeds, the local capacity needs to be built.

In this light, the National Biotechnology Development Agency (NABDA), had recently trained about 20 staff of the National Agricultural Seed Council on how to identify or detect GMOs.

The Director General of NABDA, Professor Lucy Ogbadu said Nigeria cannot afford to ignore the technology, adding that another technology which may be more acceptable to Nigerians have been discovered.

She said the new technology which is called gene editing allows the scientist to work within the confines of one genetic material instead of transferring genes from one organism to another.

We cannot afford to ignore this technology, in fact, so much advances have gone beyond where we started on genetic modification, they developed what is called gene editing and we hope that gene editing will be more acceptable to Nigeria.

Explaining what gene editing is, Professor Ogbadu said we are working within the confines of the genetic materials of one organism; we are not bringing in anything from outside into the organism, so we hope that this will be more acceptable to our people.

On the acceptability of the technology, Dr Gidado said the acceptance level in Nigeria is encouraging, more people are talking for the technology, people are beginning to see why we need it.

She further said that they are carrying the farmers along in their campaign, adding that in 2 or 3 years time, the commercialisation of BT cotton and BT cowpea will commence.

One of the environmental advantage of this technology is that less chemicals and pesticides will be used in the farm, leading to less pollution of the environment with fertilizers and chemicals.

Professor Ogbadu in her presentation a the workshop said the technology has increased environmental protection through the reduced use of pesticides and toxic chemicals.

She also said GMOs improves nutrition for people, increase quality of yields, increase farm profitability through reduced cost and new product opportunity.

Much have been said about this technology, some countries have adopted this technology and used it to advance their food production. It is important that the Nigerian government look for other means to upscale our food production.

GMOs among other biotechnology is a scientific method to improve food production in Nigeria, increase yield and practice agriculture as a business, which will in turn put money in the bags of farmers and contribute the nations GDP.

Continued here:
When OFAB gathered professionals for biotechnology - NIGERIAN TRIBUNE (press release) (blog)

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

See more here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer ... - Business Wire (press release)

"Forge is a very exciting, emerging life science company its novel platform and programs, its highly efficient business model, and its creative capitalization all attracted me to join the Board at such a pivotal time in the company's evolution," said John Schmid. "I look forward to providing strategic, operational and financial guidance to the management team in the coming years."

Dr. Worland added, "Multi-drug resistant bacteria 'superbugs' pose a very serious threat to human health and Forge's novel antibiotic program provides a promising solution to this global problem. I am honored to join the Forge Board and excited to work with its talented management team, advisors, and alliance and government partners as the company and technology platforms mature."

About the Forge Board of Directors

Forge's Board of Directors is a well-balanced composition of San Diego biotechnology industry veterans, global drug development experts and corporate finance leaders.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical companydeveloping novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has discovered novel small molecule inhibitors of LpxC that are potentin vitro, efficaciousin vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.' To complement its innovative approach to drug discovery, Forge hasa capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance itsprograms, including LpxC. Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline. For further information, please visit the company's websitewww.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:Info@ForgeTherapeutics.com

Forge Media Contact:Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-attracts-biotechnology-leaders-to-join-expanded-board-of-directors-300458043.html

SOURCE Forge Therapeutics, Inc.

http://www.forgetherapeutics.com

Read more here:
Forge Therapeutics Attracts Biotechnology Leaders To Join ... - PR Newswire (press release)

Prana Biotechnology Limited (NASDAQ:PRAN)are valued at$2.35 at the time of writing and have moved3.98% since the open. Smart investors often look for value stocks with upside potential. While this stock is priced cheaply, its important to determine if there is any actual value.

Sometimes the stock market can be very confusing, even for the most seasoned investors. Even when expectations are met as predicted, the market may decide to move otherwise. This can cause uncertainty and second guessing. Keeping up with historical data as well as short-term and long-term trends may be very helpful. Over the past week, Prana Biotechnology Limited (NASDAQ:PRAN) shares have performed -9.76%. Pushing back over the last quarter, shares are -2.20%. Looking at stock performance for the past six months, shares are -10.48%. Since the start of the calendar year, shares have performed 36.20%.

Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd.

Lets take a quick look at some possible support and resistence levels for the stock. According to a recent spotcheck, company Prana Biotechnology Limited (NASDAQ:PRAN) have been seen trading -48.69% away from the 50- day high. On the opposite end, shares have been trading 15.20% away from the 50-day low price. Taking a wider perspective, shares have been recently trading -64.87% off the 52-week high and 54.61% away from the 52-week low.

Of course, there is no easy answer to solving the tough question of how to best approach the stock market, especially when dealing with a turbulent investing climate. There are many different schools of thought when it comes to trading equities. Investors may have to first asses their appetite for risk in order to form a solid platform on which to construct a legitimate strategy. Does one run with the bulls and roar with the bears? Do they go against the grain and form a contrarian investing plan? The abundance of information with relatively easy access has made the road a bit smoother to walk for novice investors. Making the transition to the next level is where the champions are able to separate themselves from the pretenders.

See the original post here:
Is this Stock Under $5 a Bargain? Share update on Prana Biotechnology Limited (NASDAQ:PRAN) - Morgan Research

Biotechnology is one of the more tempting and complex areas of the broader healthcare sector investing. However, stock-picking in this space is tricky, which has made biotechnology exchange-traded funds popular with investors. The most popular as well as the largest biotechnology ETF is the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB).

The $8.2 billion IBBtracks the Nasdaq Biotechnology Index. The funddebuted in 2001, and currently holds 162 stocks.

While IBB has a deep bench relative to other biotechnology ETFs, investors should look under the hood to ensure this is the type of biotech fund they want to be involved with.

For example, investors often hear about biotechnology stocks that deliver jaw-dropping short-term gains on the back of favorable Food & Drug Administration (FDA) news. Then there are the biotechcompanies that are able to prove durable over time, delivering stellar returns for investors for years on end.

While it is hard to say biotechnology is a sector for conservative investors, given the historical volatility associated with the group, IBB can be viewed as one of the more conservative biotechnology ETFs due to its emphasis on the groups biggest names.

IBB is a cap-weighted ETF and as such allocates significant percentages of its weight to the biggest biotechnology names. For example, Celegene Corporation(NASDAQ:CELG), Gilead Sciences, Inc. (NASDAQ:GILD), Biogen Inc(NASDAQ:BIIB) and Amgen, Inc. (NASDAQ:AMGN) combine for nearly 31% of IBBs roster as of this writing.

Another issue to consider with IBB and biotech stocks is that the sector historically trades at valuations that are in excess of that of the healthcare sector and the broader market. Even when biotechnology is cheap by its standards, the group is likely still pricier than healthcare and broader equities benchmarks.

Volatility is also a consideration, as biotechnology stocks are more volatile than the healthcare sector. IBBs three-year standard deviation is 24.2% compared to an equivalent healthcare ETF from the iShares roster with a three-year standard deviation of 13.1%, according to issuer data.

Helped by its emphasis on large-cap biotechnology stocks, the ETF is heavily traded, sports robust liquidity and tight spreads. Those factors help minimize transaction costs and total cost of ownership.

IBB also charges 0.47% per year, or $47 annually on a $10,000 investment.

As of this writing, Todd Shriber did not hold a position in any of the aforementioned securities.

Read the rest here:
iShares Nasdaq Biotechnology Index (ETF) (IBB): The Quick Guide to IBB - Investorplace.com

By Murray McLaughlin

SARNIA, Ont. /Troy Media/ - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987).

During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

In 1970, there were roughly half as many people in the world as there are today.

In The Population Bomb (1968), Paul Ehrlich writes: "The world, especially the developing world, is rapidly running out of food ... in fact the battle to feed humanity is already lost in the sense that we will not be able to prevent large-scale famine in the next decade or so."

How was this global starvation catastrophe averted?

One element high on the list is innovation. Crop production science and innovation led to new technologies that produce more per acre and more per crop inputs.

Dr. Norman Borlaug was an American agronomist known as "the father of the Green Revolution." Borlaug developed new varieties of wheat that were planted around the world and had tremendous yield responses. His approach was adopted by other scientists to improve other crops. He was awarded the Nobel Peace Prize in 1970 for his contributions to world peace through increasing food supply. Borlaug is often credited with saving over a billion people from starvation.

With new technologies based on Borlaug's research, the successes continue. Biotechnology is a new set of tools that enhance crop breeding for new plant traits. Products from biotechnology have shown tremendous improvement since first provided to farmers in 1995. Biotech-bred crops allow farmers to reduce pesticide use, and improve quality and yields with reduced input costs. Biotech-enhanced crops are now grown by 18 million farmers, most of them in developing countries.

In Canada, corn, soybeans and canola are grown using biotechnology (often referred to as genetically-modified organisms or GMOs). All are designed to reduce pesticide use while improving yields. In 1940, corn varieties yielded 25 to 40 bushels per acre. Now, with hybrids and biotechnology, yields are typically 150 to 200 bushels per acre.

GMOs have helped Canadian farmers manage production costs, increase yields and provide safe, nutritious food to the world's consumers. There is tremendous experience and knowledge about the safety and benefits of GMO crops, based on years of development, testing and production.

The predictions of major hazards, by critics of GMO, have not materialized. GMO crops have played a vital role in improving world agricultural food production per capita. And this will be an ongoing need as the world's population heads to 10 billion people later this century.

Biotechnology in agriculture production should be embraced the same way we have embraced innovation in medicine, transportation, communication and any number of other sectors. Biotechnology will continue to help reduce global poverty.

We need more people like Borlaug. Through research, science and innovation, he helped ensure we have the necessary tools for a healthy future. Biotechnology will be an important part of that future.

Dr. Murray McLaughlin is an adviser to and former executive director of Bioindustrial Innovation Canada, based in Sarnia, Ont., and a former Saskatchewan deputy minister of agriculture.

Originally posted here:
Agricultural biotechnology crucial for feeding world population - Clearwater Times

USA Commerce Daily

Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions StockNewsJournal Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -130.59 in the trailing twelve month while Reuters data showed that industry's average ... A Look at the valuation of Puma Biotechnology, Inc. (NasdaqGS:PBYI)Business Review The Dirty Secret to Trading Puma Biotechnology, Inc. (PBYI), TETRA Technologies, Inc. (TTI)USA Commerce Daily Puma Biotechnology Inc (PBYI) PT Set at $40.00 by Royal Bank of CanadaMarkets Daily Bibeypost.com -Stocks Gallery -The De Soto Edge all 9 news articles »

Go here to read the rest:
Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions - StockNewsJournal